A detailed history of Adar1 Capital Management, LLC transactions in Ascendis Pharma A/S stock. As of the latest transaction made, Adar1 Capital Management, LLC holds 161,402 shares of ASND stock, worth $20.4 Million. This represents 3.92% of its overall portfolio holdings.

Number of Shares
161,402
Previous 51,263 214.85%
Holding current value
$20.4 Million
Previous $6.99 Billion 244.7%
% of portfolio
3.92%
Previous 1.32%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$113.0 - $153.43 $12.4 Million - $16.9 Million
110,139 Added 214.85%
161,402 $24.1 Billion
Q2 2024

Aug 13, 2024

BUY
$121.07 - $153.67 $324,346 - $411,681
2,679 Added 5.51%
51,263 $6.99 Billion
Q1 2024

May 15, 2024

BUY
$123.45 - $159.4 $333,315 - $430,380
2,700 Added 5.88%
48,584 $7.34 Billion
Q4 2023

Feb 14, 2024

BUY
$86.1 - $127.36 $3.95 Million - $5.84 Million
45,884 New
45,884 $5.78 Billion

Others Institutions Holding ASND

About Ascendis Pharma A/S


  • Ticker ASND
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,810,200
  • Market Cap $7.06B
  • Description
  • Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...
More about ASND
Track This Portfolio

Track Adar1 Capital Management, LLC Portfolio

Follow Adar1 Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Adar1 Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Adar1 Capital Management, LLC with notifications on news.